EP0194972B1 — Novel cyclosporins
Assigned to Novartis AG · Expires 1992-07-29 · 34y expired
What this patent protects
Cyclosporins e.g. of formula IIin whichX is -MeBmt- or -dihydro-MeBmt- andY is -aAbu-, Thr-, -Val- or -Nva-, wherein the residue at the 3-position, i.e. the residue Z in formula II, is an optically active, a-N-methylated a-aminoacid residue of the (D)-configuration, possess pharm…
USPTO Abstract
Cyclosporins e.g. of formula IIin whichX is -MeBmt- or -dihydro-MeBmt- andY is -aAbu-, Thr-, -Val- or -Nva-, wherein the residue at the 3-position, i.e. the residue Z in formula II, is an optically active, a-N-methylated a-aminoacid residue of the (D)-configuration, possess pharmaceutical, in particular immunosuppressive, anti-inflammatory and anti-parasitic activity. Intermediate cyclosporin poly-anions having a de-protonated sarcosyl residue at the 3-position, e.g. polyanions of cyclosporins of formula II above wherein X and Y have the meanings given above and Z is -Sar<sub>-</sub>, in which the said residue Z is de-protonated, are also novel and part of the invention.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.